This symposium addressed new developments and controversies in diabetes and endocrinology. The practical management of hyperparathyroidism, thyroid nodules, hyperprolactinaemia and diabetes and thyroid disorders in pregnancy were all discussed. In addition to these traditional areas of endocrinology, there was a focus on the role of endocrinology in ‘non-endocrine’ specialties, namely critical care and cardiovascular disease. We learned that manipulation of the thyroid axis or local glucocorticoids can potentially be used to treat high cholesterol, atrial fibrillation or coronary stent stenosis, and that glucose lowering with insulin reduces mortality in the critically ill.
Get full access to this article
View all access options for this article.
References
1.
WeiLMacDonaldTMWalkerBR.Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med2004; 141:764–70.
2.
SouvereinPCBerardAVan StaaTPUse of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart2004; 90:859–65.
3.
FilipssonHMonsonJPKoltowska-HaggstromMThe impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab2006; 91:3954–61.
4.
LiuXDe ScheerderIDesmetW.Dexamethasone-eluting stent: an anti-inflammatory approach to inhibit coronary restenosis. Expert Rev Cardiovasc Ther2004; 2:653–60.
5.
SmallGRHadokePWSharifIPreventing local regeneration of glucocorticoids by 11b-hydroxysteroid dehydrogenase type 1 enhances angiogenesis. Proc Natl Acad Sci USA2005; 102:12165–70.
ScanlanTS.Sobetirome: a case history of bench-to-clinic drug discovery and development. Heart Fail Rev 2009; in press. Epub ahead of print.
8.
HolmanRRPaulSKBethelMA10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med2008; 359:1577–89.
9.
NathanDMBuseJBDavidsonMBMedical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia2009; 52:17–30.
10.
EvansJMOgstonSAEmslie-SmithARisk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia2006; 49:930–6.
11.
HuangESMeigsJBSingerDE.The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. Am J Med2001; 111:633–42.
12.
Van den Berghe G, Baxter RC, Weekers F The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone. Clin Endocrinol (Oxf) 2002; 56:655–69.
13.
Van den Berghe G, Wouters P, Weekers F Intensive insulin therapy in the critically ill patients. N Engl J Med2001; 345:1359–67.
14.
BrunkhorstFMEngelCBloosFIntensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med2008; 358:125–39.
15.
MetzgerBELoweLPDyerARHyperglycemia and adverse pregnancy outcomes. N Engl J Med2008; 358:1991–2002.
16.
RowanJAHagueWMGaoWMetformin versus insulin for the treatment of gestational diabetes. N Engl J Med2008; 358:2003–15.
17.
AllanWCHaddowJEPalomakiGEMaternal thyroid deficiency and pregnancy complications: implications for population screening. J Med Screen2000; 7:127–30.
18.
ColaoAADi SarnoCappabiancaPWithdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med2003; 349:2023–33.
19.
OertelYCMiyahara-FelipeLMendozaMGYuK.Value of repeated fine needle aspirations of the thyroid: an analysis of over ten thousand FNAs. Thyroid2007; 17:1061–6.
20.
GravelingAJWarrenREHypoglycaemiaFrier BM.indrivingpeople with insulin-treated diabetes: adherence to recommendations for avoidance. Diabet Med2004; 21:1014–9.
